IDEXX Laboratories Inc (IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Ticker
IDXX
Exchange
Nasdaq
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$54.38B
52-week range
$500.61 - $769.98

Valuation

Share price
$698.47 (close of Nov 18, 2026)
P/E (TTM)
46.29x
Price to book
29.10x
Price to free cash flow
41.71x
Enterprise value
$55.16B
Book value per share
$23.72

Price performance

PeriodChange
1 day+1.19%
5 days-0.59%
1 month+24.65%
3 months+26.23%
6 months+27.97%
Year to date+3.24%
1 year+4.22%
3 years+50.63%
5 years+10.17%
10 years+501.46%
All time+73,787.70%

Short interest

As of
Oct 30, 2026
Short % of float
3.42%
Shares short
2.35M
Days to cover
4.45
Change since prior report
+22.02%
Source
FINRA consolidated short interest

Members of Congress who disclosed IDXX trades

April McClain Delaney · Jefferson Shreve · Robert Bresnahan · Byron Donalds

Super investors holding IDXX

Terry Smith (Fundsmith LLP) · Polen Capital Mgmt (Polen Capital Management LLC) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Wallace Weitz (Weitz Investment Management) · Mairs & Power (Mairs & Power Inc) · Bill Nygren (Harris Associates LP)

Profitability and growth

Return on equity
65.99%
Return on invested capital
42.43%
Return on assets
31.62%
Return on capital employed
61.76%
Gross margin
61.80%
Net margin
24.62%
EBITDA margin
34.97%
Revenue growth
10.42%
Net income growth
19.33%
Free cash flow growth
30.82%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.40%
Current ratio
1.19x
Net debt to EBITDA
0.46x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$4.30B
Cost of revenue
$1.64B
Gross profit
$2.66B
EBITDA
$1.51B
Net income
$1.06B
Earnings per share
$13.17
Research and development
$251.21M
Interest expense
$38.85M
Shares outstanding
80.43M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$4.30B$2.66B$1.06B$13.17
2024-12-31$3.90B$2.38B$887.87M$10.77
2023-12-31$3.66B$2.19B$845.04M$10.17
2022-12-31$3.37B$2.00B$679.09M$8.12
2021-12-31$3.22B$1.89B$744.85M$8.74
2020-12-31$2.71B$1.57B$581.78M$6.82
2019-12-31$2.41B$1.37B$427.72M$4.97
2018-12-31$2.21B$1.24B$377.03M$4.34
2017-12-31$1.97B$1.10B$263.14M$3.00
2016-12-31$1.78B$975.44M$222.04M$2.47

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3161.80%24.62%65.99%42.43%
2024-12-3161.04%22.78%55.65%35.10%
2023-12-3159.82%23.08%56.92%34.52%
2022-12-3159.52%20.17%111.56%34.53%
2021-12-3158.76%23.17%107.95%46.99%
2020-12-3158.04%21.49%91.94%37.57%
2019-12-3156.73%17.77%240.53%47.78%
2018-12-3156.10%17.04%-69.30%
2017-12-3155.73%13.36%-53.41%
2016-12-3154.94%12.51%-51.59%

Cash and debt by year

Period endCashDebt
2025-12-31$180.07M$374.84M
2024-12-31$288.27M$449.79M
2023-12-31$453.93M$622.88M
2022-12-31$112.55M$694.39M
2021-12-31$144.45M$775.21M
2020-12-31$383.93M$858.49M
2019-12-31$90.33M$698.91M
2018-12-31$123.79M$601.80M
2017-12-31$471.93M$606.60M
2016-12-31$391.85M$593.70M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.06B$60.01M
2024-12-31$808.08M$60.30M
2023-12-31$772.88M$59.74M
2022-12-31$394.15M$49.77M
2021-12-31$636.00M$37.76M
2020-12-31$541.11M$30.95M
2019-12-31$304.19M$39.28M
2018-12-31$284.33M$25.16M
2017-12-31$298.89M$23.52M
2016-12-31$274.16M$19.89M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-02Sep 2026$3.71
2026-08-04Jun 2026$3.95
2026-05-05Mar 2026$3.42
2026-02-02Dec 2025$2.93
2025-11-03Sep 2025$3.14
2025-08-04Jun 2025$3.31
2025-05-01Mar 2025$2.92
2025-02-03Dec 2024$2.40

Filings and sources

Company website
idexx.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Waters Corp (WAT) · IQVIA Holdings Inc. (IQV) · Illumina, Inc. (ILMN) · Agilent Technologies, Inc. (A) · Mettler-Toledo International Inc (MTD) · Natera, Inc. (NTRA) · Quest Diagnostics Inc (DGX) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades